Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study
Survival after start of radium-223 in Sweden was comparable to pivotal trials, suggesting effective use. Our overall results do not suggest a better effect of radium-223 in first versus later mCRPC treatment lines but rather emphasize the value of a randomized controlled trial to more definitely determine the optimal timing of radium-223 treatment.
Authors
- Fredrik Sandin
- Charlotte Alverbratt (ORCID: https://orcid.org/0000-0002-8554-1046)
- Ola Bratt (ORCID: https://orcid.org/0000-0002-9198-9445)
- Hans Garmo (ORCID: https://orcid.org/0000-0001-7181-7083)
- Ingela Franck Lissbrant (ORCID: https://orcid.org/0000-0001-8612-9814)
- Viktor Kolmbäck
Institutions
- Uppsala University (SE)
- Uppsala University Hospital (SE)
- Varberg Hospital (SE)
- Sahlgrenska University Hospital (SE)
- Regional Research Council in Uppsala-Örebro Region (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-10-13
- DOI
- https://doi.org/10.2340/1651-226x.2025.43794
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Foundation
- Fondation contre le Cancer